{"disease":{"id":"chronic-hepatitis-c-infection","name":"chronic hepatitis c infection"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02578693","title":"Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)","phase":"","overall_status":"COMPLETED","enrollment_count":1210,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT04387526","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05792878","title":"Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT01866930","title":"Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":453,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04382937","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT02442271","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02583685","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":138,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT03453346","title":"Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C","phase":"NA","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Kawin Technology Share-holding Co., Ltd.","has_results":false},{"nct_id":"NCT01782495","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04391985","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT03495570","title":"Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04387539","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02292719","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02486406","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02772003","title":"DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01194037","title":"A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"HanAll BioPharma Co., Ltd.","has_results":false},{"nct_id":"NCT02356562","title":"A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07487623","title":"Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","phase":"NA","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"University of Guadalajara","has_results":false},{"nct_id":"NCT04638439","title":"The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT03723824","title":"Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT04019717","title":"Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05674448","title":"A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Huahui Health","has_results":false},{"nct_id":"NCT01586325","title":"A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Janssen R&D Ireland","has_results":false},{"nct_id":"NCT00954993","title":"Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}